Efferon
Efferon
Develops multimodal hemoadsorption therapeutic devices for sepsis and septic shock.
About
What does Efferon do?
Efferon is a biotech company specializing in the development of multimodal hemoadsorption therapeutic devices. Their core technology aims to remove endotoxins and inflammatory mediators directly from the bloodstream. The company's product portfolio includes Efferon LPS, a hemoadsorption cartridge for endotoxin and cytokine adsorption, and Efferon NEO, a version specifically designed for pediatric use. These devices are intended to support faster stabilization of septic shock, reduce time on mech…
What is Efferon's revenue?
StartupHub estimates Efferon's annual revenue at $1.9M (range $552K to $6.9M, 35% confidence), based on comparable companies in the sector.
What is Efferon's valuation?
StartupHub estimates Efferon's effective valuation at $71.4M (range $43.8M to $105.0M, 24% confidence), based on comparable companies in the sector.
How much funding has Efferon raised?
Efferon has raised a total of $18M in funding. The most recent round on record is Seed.
Where is Efferon headquartered?
Efferon is headquartered in Tel Aviv, Israel.
When was Efferon founded?
Efferon was founded in 2017.
What industry does Efferon operate in?
Efferon operates in Biotechnology, Medical Devices, Healthcare, Biotech, MedTech, HealthTech.
No comments yet. Be the first to share your take.